combination insulin glp 1 of basal and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes? | Diabetology & Metabolic Syndrome It might be the era

and generic manufacturers positioning for biosimilar competition from 2031 onward

Nutritional patterns can either enhance or hinder the medications effectscertain macronutrient compositions lead to better insulin response, digestion efficiency, and metabolic adaptations

Zepbound (tirzepatide) injection: prescribing information

On the negative side of things, the FDA updated the label for Ozempic with a warning about intestinal blockages after multiple reports of the rare but severe side effect

Yes, rapid escalation can increase the risk of nausea, vomiting, dehydration, and in rare cases, pancreatitis or gallbladder issues

This is usually not a patient's first rodeo with nutrition counseling, Basilico emphasized